Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for garadacimab (CSL312) as a once-monthly prophylactic treatment for hereditary angioedema (HAE).
| |
| [14-December-2023] |
| These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has been serving for over 40 years, in the U.S. and European Union. KING OF PRUSSIA, Penn., Dec. 14, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for garadacimab (CSL312) as a once-monthly prophylactic treatment for hereditary angioedema (HAE). The company also announced the European Medicines Agency (EMA) has accepted the submission for CSL’s Marketing Authorization Application (MAA) for garadacimab. If approved, garadacimab would become the first treatment for HAE in the U.S. and EU to target activated Factor XII (FXIIa).
Garadacimab is a novel, first-in-class, recombinant monoclonal antibody targeting activated FXII. FXIIa is a plasma protein that initiates the kallikrein-kinin cascade of HAE attacks. By targeting FXIIa, garadacimab inhibits this cascade at the top as compared to HAE therapies that target downstream mediators. “CSL is a company with a deep heritage in developing innovative treatments for the rare disease community, and we are extremely proud that our first homegrown recombinant monoclonal antibody is progressing our commitment to support HAE patients in need,” said Emmanuelle Lecomte Brisset, Pharm D, Senior Vice President and Global Head of Regulatory Affairs at CSL. “We believe that garadacimab has the potential to become a promising therapy in the prevention of HAE attacks and we look forward to working closely with global health regulators throughout the review process.” Orphan-drug designation for garadacimab as a therapy for hereditary angioedema has been granted by both the FDA and the EMA. The BLA and MAA are both supported by data from the pivotal, multicenter, randomized, double-blind, parallel-group VANGUARD trial, which evaluated the efficacy and safety of garadacimab as a prophylactic treatment for patients with HAE. The full results from VANGUARD were published in The Lancet (April 2023). The ongoing open-label extension of the VANGUARD study evaluates the long-term safety and efficacy of garadacimab (200 mg monthly) in patients with HAE. About HAE and Garadacimab Garadacimab is a novel Factor XIIa-inhibitory monoclonal antibody (anti-FXIIa mAb) that has completed Phase 3 clinical development as a potential new type of once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema. Garadacimab uniquely inhibits the plasma protein, FXIIa. When FXII is activated, it initiates the cascade of events leading to edema formation. By targeting activated FXII (FXIIa), garadacimab inhibits this cascade at the top as compared to HAE therapies that target downstream mediators. If approved, patients will have the benefit of an auto injector (pre-filled pen) for convenient administration. CSL is also investigating garadacimab for other indications beyond HAE, including idiopathic pulmonary fibrosis, where FXIIa inhibition may play an important role in improving clinical outcomes. About CSL For more information about CSL, visit www.CSL.com. Media Contact In Australia: Jimmy Baker
SOURCE CSL | ||
Company Codes: Australia:CSL, OTC-PINK:CSLLY, OTC-BB:CSLLY |
View original content to download multimedia:
